A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects

• Sponsor: Sunshine Lake Pharma Co., Ltd. (Industry)
• Overall Status: Completed
• CT.gov ID: NCT05459285
• Collaborator: (none)
• Enrollment: 68
• Location: 1
• Arms: 2
• Actual Duration (Months): 1.2
• Patients Per Site Per Month: 54.5

Study Details

Study Description

Brief Summary

To evaluate the pharmacokinetics similarity between the 14028 injection produced by Sunshine Lake Pharma Co., Ltd. and dulaglutide injection (TRULICITY®) produced by Eli Lilly and Company for single dose in healthy male subjects, as well as to evaluate the similarity of the safety and immunogenicity between 14028 Injection and TRULICITY® in Healthy Subjects

Condition or Disease	Intervention/Treatment	Phase
Type 2 Diabetes	Biological: 14028 injection; Biological: dulaglutide injection	Phase 1

Study Design

• Study Type: Interventional
• Actual Enrollment: 68 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Pharmacokinetics, Safety and Immunogenicity of 14028 Injection Versus Dulaglutide Injection in Healthy Subjects: a Phase I ，Single-center, Randomized, Open-label, Single-dose, Parallel-controlled Clinical Study
• Actual Study Start Date: May 31, 2022
• Actual Primary Completion Date: Jul 2, 2022
• Actual Study Completion Date: Jul 8, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 14028 injection Subjects receive 14028 injection in the study, 0.75mg, once	Biological: 14028 injection; 14028 injection, single dose, s.c. injection
Active Comparator: dulaglutide injection (TRULICITY®) Subjects receive dulaglutide injection (TRULICITY®) in the study, 0.75mg, once	Biological: dulaglutide injection; dulaglutide injection(TRULICITY®), single dose, s.c. injection; Other Names: TRULICITY®

Outcome Measures

Primary Outcome Measures

1. Maximum (peak) plasma drug concentration(Cmax) [0 hour (pre-dose,within 30mins) to 384 hours after administration]

   Maximum (peak) plasma drug concentration

2. Area under the plasma concentration-time curve from time zero to ∞ (AUC0-∞) [0 hour (pre-dose, within 30mins) to infinity]

   The area under the plasma concentration curve from 0 to ∞

Secondary Outcome Measures

1. Area under the plasma concentration-time curve from time zero to time t (AUC0-t) [0 hour (pre-dose,within 30mins) to 384 hours after administration]

   The area under the plasma concentration curve from 0 to 384 h

2. Time to reach maximum plasma concentration following drug administration (Tmax) [0 hour (pre-dose,within 30mins) to 384 hours after administration]

   Time to maximum concentration

3. Elimination half-life (t1/2) [0 hour (pre-dose,within 30mins) to 384 hours after administration]

   Elimination half-life

4. Apparent total body clearance (CL/F) [0 hour (pre-dose,within 30mins) to 384 hours after administration]

   Apparent total body clearance

5. Apparent volume of distribution (Vd/F) [0 hour (pre-dose,within 30mins) to 384 hours after administration]

   Apparent volume of distribution

6. Elimination constants (λz) [0 hour (pre-dose,within 30mins) to 384 hours after administration]

   Elimination constants

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 45 Years
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. Sign the informed consent form before the trial, understand and comply with the research process, and participate the trial voluntarily

2. Healthy male subjects aged 18 to 45 (including the critical value)

3. Weight > or = 50 kg, and 19.0 kg/m2 < or = BMI (body mass index) < or = 28.0 kg/m2

4. Vital signs, physical examination, laboratory examination, electrocardiogram, thyroid color Doppler ultrasound, abdominal color Doppler ultrasound and chest X-ray (anteroposterior) and other test results during screening are normal or have no clinical significance as judged by the investigator

5. Subjects agree to use effective contraceptive methods from signing the informed consent form to the end of the trial drug use within 3 months, and there is no sperm donation plan.

Exclusion Criteria:

1. The investigator judges that the subjects have the following clinically significant diseases (including but not limited to gastrointestinal, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases)

2. Have a medical or family history of medullary thyroid cancer (grandparents, parents, brothers and sisters), or a genetic disease that lead to medullary thyroid cancer; or a history or family history of multiple endocrine neoplasia syndrome type 2

3. Past or current history of pancreatitis (chronic or acute pancreatitis)

4. Past or current history of habitual constipation or intestinal obstruction

5. Clinically significant history of drug allergy or specific allergic disease (asthma, urticaria) or known allergy to the investigational drug and any component or related excipient components

6. Those who have difficulty with venous blood collection, a history of needle sickness, haemorrhage, or a known tendency to severe bleeding

7. Positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), human immunodeficiency virus antibody (HIV), and Treponema pallidum antibody (TPAb)

8. Those who have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines, health products (except vitamin supplements) within 2 weeks before the first dose

9. Those who have a history of vaccination with live attenuated vaccine within 3 months before screening or a history of vaccination with inactivated vaccine within 1 month before screening

10. Those who have previously received dulaglutide or any other glucagon-like peptide-1 (GLP-1) analog

11. Those who donated blood or lost blood > or = 400 mL within 3 months before screening, or those who plan to donate blood

12. Those who smoked more than 5 cigarettes per day within 3 months before screening or who could not give up smoking during the period from signing the informed consent to the subjects leaving the group

13. Those who have a history of alcohol abuse, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) , or those who have a positive alcohol breath test during the screening period

14. Those who have a history of drug abuse or poison use within 2 years before screening, or those who have a positive test results for urine drug abuse screening during the screening period

15. Participated in other clinical trials within 3 months before screening (subjects who are not randomized or not receiving treatment withdraw from the study before treatment, they can be enrolled in this study)

16. Acute illness or concomitant medication occurred from the time of signing the informed consent to the first administration

17. Those who have special requirements for diet and cannot obey the unified diet

18. Others judged by the investigator to be unsuitable to participate in this trial

19. Subjects who may not be able to complete this trial for other reasons

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	PKUCare Luzhong Hospital	Zibo	Shandong	China	255400

Sponsors and Collaborators

• Sunshine Lake Pharma Co., Ltd.

Investigators

• Principal Investigator: Jie Hou, doctor, Peking University Care Luzhong Hospital
• Principal Investigator: Hong Wang, bachelor, Peking University Care Luzhong Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

• Barrington P, Chien JY, Showalter HD, Schneck K, Cui S, Tibaldi F, Ellis B, Hardy TA. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011 May;13(5):426-33. doi: 10.1111/j.1463-1326.2011.01364.x. Epub 2011 Jan 19.
• Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab. 2011 May;13(5):434-8. doi: 10.1111/j.1463-1326.2011.01365.x. Epub 2011 Jan 19.
• de la Peña A, Cui X, Geiser J, Loghin C. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. Clin Pharmacokinet. 2017 Nov;56(11):1415-1427. doi: 10.1007/s40262-017-0531-7.
• EMA (European Medicines Agency), Public assessment report.2014
• EMA. Trulicity® Risk Management Plan.2021.01.02.
• FDA (Food Drug Administration), Clinical Pharmacology Biopharmaceutics Review(s), 2014.
• FDA. Guidance for Industry - Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Dec. 2016.
• Geiser JS, Heathman MA, Cui X, Martin J, Loghin C, Chien JY, de la Peña A. Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials. Clin Pharmacokinet. 2016 May;55(5):625-34. doi: 10.1007/s40262-015-0338-3.
• IDF (International Diabetes Federation) Diabetes Atlas, ninth edition, 2019.

• Responsible Party: Sunshine Lake Pharma Co., Ltd.
• ClinicalTrials.gov Identifier: NCT05459285
• Other Study ID Numbers: 14028-DM-101
• First Posted: Jul 14, 2022
• Last Update Posted: Aug 25, 2022
• Last Verified: Aug 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Dulaglutide

Study Results

No Results Posted as of Aug 25, 2022